Immunotherapy coming of age: What will it take to make it standard of care for glioblastoma?

被引:76
作者
Heimberger, Amy B. [1 ]
Sampson, John H. [2 ,3 ,4 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA
[2] Duke Univ, Med Ctr, Div Neurosurg, Dept Surg, Durham, NC 27710 USA
[3] Duke Univ, Med Ctr, Preston Robert Tisch Brain Tumor Ctr, Durham, NC USA
[4] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA
关键词
clinical trial; glioblastoma multiforme; immunotherapy; malignant gliomas; T-CELL RESPONSES; CENTRAL-NERVOUS-SYSTEM; RECOMBINANT INTERLEUKIN-2 THERAPY; AUTOLOGOUS TUMOR-CELLS; CERVICAL LYMPH-NODES; LONG-TERM SURVIVAL; METASTATIC MELANOMA; DENDRITIC CELLS; PEPTIDE VACCINATION; CEREBROSPINAL-FLUID;
D O I
10.1093/neuonc/noq169
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
With the recent approval by the FDA of an immunotherapy for prostate cancer and another positive immunotherapy trial in melanoma, immunotherapy may finally be coming of age. So what will it take for it to become part of the standard treatment for glioblastoma? To put this question into perspective, we summarize critical background information in neuro-immunology, address immunotherapy clinical trial design, and discuss a number of extrinsic factors that will impact the development of immunotherapy in neuro-oncology.
引用
收藏
页码:3 / 13
页数:11
相关论文
共 143 条
[1]   Regulation of T-cell responses by CNS antigen-presenting cells: different roles for microglia and astrocytes [J].
Aloisi, F ;
Ria, F ;
Adorini, L .
IMMUNOLOGY TODAY, 2000, 21 (03) :141-147
[2]   Phenotypic analysis of antigen-specific T lymphocytes [J].
Altman, JD ;
Moss, PAH ;
Goulder, PJR ;
Barouch, DH ;
McHeyzerWilliams, MG ;
Bell, JI ;
McMichael, AJ ;
Davis, MM .
SCIENCE, 1996, 274 (5284) :94-96
[3]   High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993 [J].
Atkins, MB ;
Lotze, MT ;
Dutcher, JP ;
Fisher, RI ;
Weiss, G ;
Margolin, K ;
Abrams, J ;
Sznol, M ;
Parkinson, D ;
Hawkins, M ;
Paradise, C ;
Kunkel, L ;
Rosenberg, SA .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :2105-2116
[4]  
Atkins MB, 2000, CANCER J SCI AM, V6, pS11
[5]   Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma [J].
Attia, P ;
Maker, AV ;
Haworth, LR ;
Rogers-Freezer, L ;
Rosenberg, SA .
JOURNAL OF IMMUNOTHERAPY, 2005, 28 (06) :582-592
[6]  
BERD D, 1987, CANCER RES, V47, P3317
[7]   Antigen-specific T-cell-mediated immunity after HIV-1 infection: implications for vaccine control of HIV development [J].
Betts, Michael R. ;
Gray, Clive M. ;
Cox, Josephine H. ;
Ferrari, Guido .
EXPERT REVIEW OF VACCINES, 2006, 5 (04) :505-516
[8]   HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells [J].
Betts, Michael R. ;
Nason, Martha C. ;
West, Sadie M. ;
De Rosa, Stephen C. ;
Migueles, Stephen A. ;
Abraham, Jonathan ;
Lederman, Michael M. ;
Benito, Jose M. ;
Goepfert, Paul A. ;
Connors, Mark ;
Roederer, Mario ;
Koup, Richard A. .
BLOOD, 2006, 107 (12) :4781-4789
[9]   Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection [J].
Betts, MR ;
Exley, B ;
Price, DA ;
Bansal, A ;
Camacho, ZT ;
Teaberry, V ;
West, SM ;
Ambrozak, DR ;
Tomaras, G ;
Roederer, M ;
Kilby, JM ;
Tartaglia, J ;
Belshe, R ;
Gao, F ;
Douek, DC ;
Weinhold, KJ ;
Koup, RA ;
Goepfert, P ;
Ferrari, G .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (12) :4512-4517
[10]   Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma [J].
Boasberg, Peter D. ;
Hoon, Dave S. B. ;
Piro, Lawrence D. ;
Martin, Maureen A. ;
Fujimoto, Akhide ;
Kristedja, Timothy S. ;
Bhachu, Sandeep ;
Ye, Xing ;
Deck, Regina R. ;
O'Day, Steven J. .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2006, 126 (12) :2658-2663